ストックスクリーナーアプリを入手
4.26
13.75%
0.515
アフターアワーズ：
4.35
0.09
+2.11%
前日終値:
$3.745
開ける：
$3.8
24時間の取引高:
24.50M
Relative Volume:
1.90
時価総額：
$1.75B
収益：
$241.53M
当期純損益:
$-389.92M
株価収益率:
-3.4634
EPS:
-1.23
ネットキャッシュフロー:
$-323.54M
1週間 パフォーマンス:
+11.23%
1か月 パフォーマンス:
+74.59%
6か月 パフォーマンス:
+93.64%
1年 パフォーマンス:
+8.67%
1日の値動き範囲:
$3.73
$4.28
1週間の範囲:
$3.50
$4.28
52週間の値動き範囲:
$1.6385
$4.35
Iovance Biotherapeutics Inc Stock (IOVA) Company Profile
名前
Iovance Biotherapeutics Inc
セクター
電話
(650) 260-7120
住所
825 INDUSTRIAL ROAD, SAN CARLOS
Compare IOVA vs VRTX, REGN, ARGX, ALNY, ONC
| 株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
|---|---|---|---|---|---|---|
IOVA
Iovance Biotherapeutics Inc
|
4.26 | 1.54B | 241.53M | -389.92M | -323.54M | -1.23 |
|
VRTX
Vertex Pharmaceuticals Inc
|
477.89 | 120.48B | 12.07B | 3.95B | 3.19B | 15.33 |
|
REGN
Regeneron Pharmaceuticals Inc
|
787.50 | 81.05B | 14.34B | 4.50B | 3.77B | 41.56 |
|
ARGX
Argen X Se Adr
|
749.56 | 46.33B | 4.16B | 1.29B | 734.26M | 19.59 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
327.30 | 42.26B | 3.71B | 313.75M | 465.38M | 2.2571 |
|
ONC
Beone Medicines Ltd Adr
|
299.02 | 32.87B | 5.36B | 287.73M | 924.18M | 2.5229 |
Iovance Biotherapeutics Inc Stock (IOVA) Upgrades & Downgrades
| 日付 | アクション | アナリスト | 評価の変更 |
|---|---|---|---|
| 2025-07-15 | ダウングレード | Goldman | Neutral → Sell |
| 2025-05-16 | ダウングレード | UBS | Buy → Neutral |
| 2025-05-12 | ダウングレード | Truist | Buy → Hold |
| 2025-05-09 | ダウングレード | Citizens JMP | Mkt Outperform → Mkt Perform |
| 2024-10-24 | 開始されました | UBS | Buy |
| 2024-07-29 | ダウングレード | Piper Sandler | Overweight → Neutral |
| 2023-11-20 | 開始されました | Goldman | Buy |
| 2023-09-18 | 繰り返されました | Barclays | Overweight |
| 2023-05-30 | アップグレード | Wells Fargo | Equal Weight → Overweight |
| 2023-03-27 | 再開されました | Wells Fargo | Equal Weight |
| 2023-01-27 | アップグレード | Piper Sandler | Neutral → Overweight |
| 2022-12-09 | ダウングレード | Goldman | Buy → Neutral |
| 2022-10-31 | 開始されました | Guggenheim | Neutral |
| 2022-08-18 | 再開されました | Wells Fargo | Equal Weight |
| 2022-01-28 | アップグレード | Stifel | Hold → Buy |
| 2021-12-07 | 再開されました | Cowen | Outperform |
| 2021-06-10 | アップグレード | JMP Securities | Mkt Perform → Mkt Outperform |
| 2021-05-20 | ダウングレード | Piper Sandler | Overweight → Neutral |
| 2021-05-19 | ダウングレード | JMP Securities | Mkt Outperform → Mkt Perform |
| 2021-05-19 | ダウングレード | Stifel | Buy → Hold |
| 2021-05-03 | 開始されました | Truist | Buy |
| 2021-04-16 | 開始されました | Goldman | Buy |
| 2021-03-08 | アップグレード | H.C. Wainwright | Neutral → Buy |
| 2020-12-15 | ダウングレード | H.C. Wainwright | Buy → Neutral |
| 2020-10-06 | ダウングレード | Wells Fargo | Overweight → Equal Weight |
| 2020-04-22 | 開始されました | Mizuho | Buy |
| 2020-03-04 | 開始されました | Barclays | Overweight |
| 2020-02-26 | 繰り返されました | H.C. Wainwright | Buy |
| 2020-02-26 | 繰り返されました | Oppenheimer | Outperform |
| 2019-12-18 | 開始されました | JMP Securities | Mkt Outperform |
| 2019-10-01 | 開始されました | Stifel | Buy |
| 2019-04-29 | 開始されました | Piper Jaffray | Overweight |
| 2019-02-28 | 繰り返されました | Chardan Capital Markets | Buy |
| 2019-02-07 | 開始されました | Robert W. Baird | Outperform |
| 2018-12-31 | 再開されました | B. Riley FBR | Buy |
| 2018-07-06 | 繰り返されました | Chardan Capital Markets | Buy |
| 2018-04-10 | アップグレード | B. Riley FBR, Inc. | Neutral → Buy |
| 2018-03-13 | 繰り返されました | B. Riley FBR, Inc. | Neutral |
| 2018-02-23 | ダウングレード | B. Riley FBR, Inc. | Buy → Neutral |
| 2018-01-25 | 繰り返されました | H.C. Wainwright | Buy |
| 2017-11-01 | 繰り返されました | B. Riley FBR, Inc. | Buy |
すべてを表示
Iovance Biotherapeutics Inc (IOVA) 最新ニュース
RSU vesting boosts Iovance (NASDAQ: IOVA) CRO share holdings - Stock Titan
Iovance Biotherapeutics (NASDAQ:IOVA) Trading 9.9% Higher After Analyst Upgrade - MarketBeat
Iovance Biotherapeutics’ TIL Therapy Showcases Promising Results - StocksToTrade
Iovance Biotherapeutics: Short-Term Pain, Long-Term GainI'm Still Bullish After All These Years - Seeking Alpha
Iovance Biotherapeutics’ Stock Rallies After Promising Trial Data - timothysykes.com
Iovance Biotherapeutics Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4) - 富途牛牛
Citizens Upgrades Iovance Biotherapeutics (IOVA) - Nasdaq
Assessing Iovance Biotherapeutics (IOVA) Valuation After Amtagvi Momentum And New Fast Track Designation - Sahm
IOVA Receives Analyst Upgrade to Market Outperform by Citizens | - GuruFocus
Citizens Jmp Upgrades Iovance Biotherapeutics (NASDAQ:IOVA) to "Market Outperform" - MarketBeat
A Glimpse Into The Expert Outlook On Iovance Biotherapeutics Through 4 Analysts - Benzinga
This Unity Software Analyst Is No Longer Bearish; Here Are Top 4 Upgrades For Tuesday - Benzinga
Iovance Biotherapeutics, Inc. (NASDAQ:IOVA) Short Interest Up 24.8% in February - MarketBeat
Iovance Biotherapeutics (NASDAQ:IOVA) Gains Visibility Across The Nasdaq Index - Kalkine Media
Iovance Biotherapeutics, Inc. (NASDAQ:IOVA) Given Average Recommendation of "Hold" by Brokerages - MarketBeat
IOVA: AMTAGVI drives robust growth as pipeline advances toward major milestones in lung and sarcoma - TradingView
symbol__ Stock Quote Price and Forecast - CNN
Iovance Lifileucel Progress Reshapes Growth Prospects Beyond Melanoma - Yahoo Finance
IOVA Stock News Today | Earnings, Events & Price Alerts - Intellectia AI
Why Iovance Biotherapeutics (IOVA) Is Up 34.5% After Amtagvi-Fueled Revenue Jump And Lifileucel Fast Track - Sahm
Wall Street Zen Upgrades Iovance Biotherapeutics (NASDAQ:IOVA) to Hold - MarketBeat
Iovance Biotherapeutics, Inc. (IOVA) Stock Analysis: Potential Upside of 132% Amid Rising Investor Interest - DirectorsTalk Interviews
Is Iovance Biotherapeutics (IOVA) Pricing Reflect Recent Cell Therapy Progress Accurately - Yahoo Finance
IOVA Should I Buy - Intellectia AI
Iovance (NASDAQ: IOVA) CCO vests 120,000 PSUs, withholds shares for tax - Stock Titan
Iovance Biotherapeutics (IOVA) Reports 61% Annual Revenue Growth Driven by Amtagvi Success - Yahoo Finance
Strategic Milestones Propel Iovance Biotherapeutics Inc. - StocksToTrade
Cancer biotech Iovance plans March talks at TD Cowen and Barclays events - Stock Titan
Brokers Set Expectations for IOVA Q1 Earnings - MarketBeat
Guidance Update: Whats the beta of Iovance Biotherapeutics Inc stockQuarterly Profit Report & Smart Swing Trading Techniques - baoquankhu1.vn
1 Nearly Unknown Biotech Stock Set To Go Parabolic If Its Pipeline Hits - AOL.com
IOVA Beats on Q4 Earnings & Sales, Stock Soars on Pipeline Progress - The Globe and Mail
Iovance Highlights Amtagvi Revenue Growth and Profitability Path - The Globe and Mail
Key facts: Iovance's Lifileucel gains Fast Track; Barclays raises target to $11 - TradingView
Iovance Surged 44% This Week and Its Philadelphia Factory Explains Why - Yahoo Finance
Iovance Biotherapeutics (IOVA) Analyst Raises Price Target to $1 - GuruFocus
Iovance Biotherapeutics Surges Amid Encouraging Sarcoma Therapy Data - timothysykes.com
Barclays Boosts Iovance Biotherapeutics (NASDAQ:IOVA) Price Target to $11.00 - MarketBeat
Iovance Biotherapeutics (NASDAQ:IOVA) Sees Strong Trading Volume Following Earnings Beat - MarketBeat
Iovance Biotherapeutics TIL Therapy Shows Promising Upside - StocksToTrade
Chardan Capital Has Lowered Expectations for Iovance Biotherapeutics (NASDAQ:IOVA) Stock Price - MarketBeat
Iovance Biotherapeutics (NASDAQ:IOVA) Raised to Market Outperform at Citizens Jmp - MarketBeat
Iovance Biotherapeutics, Inc. (NASDAQ:IOVA) Q4 2025 Earnings Call Transcript - Insider Monkey
IOVA Stock Upgraded to Market Outperform by Citizens Analyst | I - GuruFocus
Iovance Biotherapeutics stock rating upgraded on revenue growth By Investing.com - Investing.com Canada
Iovance Biotherapeutics Q4 Loss Narrows To US$0.18 EPS And Tests Bearish Narratives - simplywall.st
Iovance Biotherapeutics stock rating upgraded on revenue growth - Investing.com
Iovance Biotherapeutics Reports Record Q4 Margins and Strong Upside Potential - Intellectia AI
After IOVA Stock’s Best Day In 2 Years, Analyst Sees Over 300% Upside: Here’s Why - Stocktwits
Iovance Biotherapeutics Inc (IOVA) Q4 2025 Earnings Call Highlig - GuruFocus
Decoding Iovance Biotherapeutics Inc (IOVA): A Strategic SWOT In - GuruFocus
Iovance Biotherapeutics Inc (IOVA) 財務データ
収益
当期純利益
現金流量
EPS
0.11%
6.00%
大文字化:
|
ボリューム (24 時間):